Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01954576 · ClinicalTrials.gov registry record · NA
NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
A NA study, sponsored by University of Florida.
- Terminated
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT01954576: Clinical Trial NA study, sponsored by University of Florida.
NCT01954576 is a NA study that was terminated before completion, run by University of Florida. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01954576, a NA study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
This pilot phase II trial studies how well Novocure's Tumor Treating Electric Fields (NovoTTF) therapy works in treating patients with recurrent glioblastoma multiforme. NovoTTF therapy uses a low intensity electric current to kill tumor cells. NovoTTF therapy may be effective treatment for brain cancer.
Primary Outcome
Response and progression evaluated using Response Assessment in Neuro-Oncology (RANO). Response is evaluated with the use of MRI every 8 weeks. A Fisher's exact test with two-sided 0.05 and 80% power will be used.
Interventions
- PROCEDURE Quality-of-life assessment
- DEVICE NovoTTF-100A
- GENETIC Laboratory biomarker analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-10-10 |
| Est. Completion | 2021-05-14 |
| Phase | NA |
Why NCT01954576 stopped before completion
NCT01954576 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Quality-of-life assessment is the first listed.
NCT01954576 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01954576 about?
NCT01954576 is a clinical study titled "NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme". This pilot phase II trial studies how well Novocure's Tumor Treating Electric Fields (NovoTTF) therapy works in treating patients with recurrent glioblastoma multiforme. NovoTTF therapy uses a low intensity electric current to kill tumor cells. NovoTTF therapy may be effective treatment for brain ca...
What is the current status of trial NCT01954576?
This trial is currently terminated. It is a NA study. The enrollment target is 21 participants. The study started on 2013-10-10. Estimated completion is 2021-05-14.
What interventions are being tested in trial NCT01954576?
The interventions under investigation include: Quality-of-life assessment (PROCEDURE), NovoTTF-100A (DEVICE), Laboratory biomarker analysis (GENETIC).
Who is sponsoring clinical trial NCT01954576?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01954576's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI